

5/1642

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on

January 3, 2003

Cynthia P. Scanio
Cynthia P. Scanio

January 3, 2003
Date

#5

Serial No: 10/068,067
Filed: February 5, 2002
Applicant: Marc E. Rothenberg, et al.
Title: REGULATION OF CCR3 EXPRESSION
Art Unit: 1642
Examiner: unknown
Atty. Dkt.: CMC/153

RECEIVED

JAN 10 2003

TECH CENTER 1600/2900

Cincinnati, Ohio 45202

January 3, 2003

Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. §§1.56, 1.97 and 1.98, the references listed on the attached supplemental Form PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. Copies of the cited references are attached hereto. No representation is made that the cited art is the only art or that the cited art represents the most material art.

A copy of the International Search Report in the counterpart PCT patent application is enclosed. This Search Report was mailed on December 12, 2002, and cites three references that were not previously cited to the United States Patent and Trademark Office: International Publication No. WO 95/12415; Nirodi, et al. "The role of CDP in the

Negative Regulation of CXCL1 Gene Expression"; and Yamaguchi, et al. "Mechanisms of Transcription in Eosinophils: GATA-1, but not GATA-2, Transactivates the Promoter of the Eosinophil Granule Major Basic Protein Gene".

The Examiner is urged to consider each of the cited references listed on the attached supplemental Form PTO-1449, and to make an independent decision with respect to its materiality.


Certification under 37 C.F.R. §1.97(e)

Each item of information contained in the Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information disclosure Statement.

Applicants do not believe that any fees are due in connection with this submission. However, should any fees be deemed required, the Commissioner is hereby authorized to charge any such fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.



Beverly A. Lyman, Ph.D.
Reg. No. 41,961

WOOD, HERRON & EVANS, L.L.P.
2700 Carew Tower
441 Vine Street
Cincinnati, Ohio 45202-2917
(513) 241-2324 (voice)
(513) 421-7269 (facsimile)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/068,067SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

RECEIVED

JAN 10 2003

TECH CENTER 1600/2900

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L	WO 95/12415	11 May 1995	PCT	A61K 48/00	C07H 21/00	
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	Nirodi, et al., <u>The Role of CDP in the Negative Regulation of CXCL1 Gene Expression</u> , Journal of Biological Chemistry, Vol. 276, No. 28, July 13 2001, pp. 26122-26131.
A.S	Yamaguchi, et al., <u>Mechanisms of Transcription in Eosinophils: GATA-1, but not GATA-2, Transactivates the Promoter of the Eosinophil Granule Major Basic Protein Gene</u> , Blood, Vol. 91, No. 9, May 1 1998, pp. 3447-3458.
A.T	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.
Include a copy of this form with next communication to applicant.